Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 48Lymphoma 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, Non-Hodgkin 23Osteosarcoma 21Hodgkin Disease 17Testicular Neoplasms 16Burkitt Lymphoma 13Testicular Germ Cell Tumor 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Ovarian Neoplasms 12Teratoma 9Neuroectodermal Tumors, Primitive, Peripheral 9Lymphoma, Large-Cell, Immunoblastic 9Lymphoma, Follicular 9Neuroblastoma 8Lymphoma, Large-Cell, Anaplastic 8Central Nervous System Neoplasms 8Recurrence 7Lymphoma, Mantle-Cell 7Lymphoma, B-Cell 7Leukemia 7Endodermal Sinus Tumor 7Seminoma 6Rhabdomyosarcoma 6Lymphoma, B-Cell, Marginal Zone 6Breast Neoplasms 6Small Cell Lung Carcinoma 5Neoplasms, Germ Cell and Embryonal 5Neoplasms 5

Interventions

pembrolizumab 2fludarabine 2Radiosurgery 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1regorafenib 1pazopanib 1niraparib 1neratinib 1lutetium Lu 177 dotatate 1ibrutinib 1grapiprant 1fludarabine phosphate 1famitinib 1encorafenib 1copanlisib 1cemiplimab 1capivasertib 1camrelizumab 1brigatinib 1binimetinib 1axicabtagene ciloleucel 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Disease Progression × Ifosfamide × Clear all
NCT04044378 2020-05-19

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Peking University People's Hospital

Phase 1/2 Withdrawn

Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡